{"filing":{"accession_number":"0001193125-26-278582","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"d161847d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm"},"events":[{"id":13039,"run_id":11569,"accession_number":"0001193125-26-278582","anchor_item_number":"1.03","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"summary":"Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. The company will operate as a debtor-in-possession and has filed motions for first-day relief and debtor-in-possession financing.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10071,"accession_number":"0001193125-26-278582","item_number":"1.03","item_title":"Bankruptcy or Receivership.","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. The company will operate as a debtor-in-possession and has filed motions for first-day relief and debtor-in-possession financing. This is an unambiguous bankruptcy filing—a terminal event materially threatening the registrant's continued existence as an independent operating company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13040,"run_id":11569,"accession_number":"0001193125-26-278582","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"In connection with its Chapter 11 bankruptcy proceedings, Sangamo entered into stalking horse asset purchase agreements, a mechanism used in bankruptcy proceedings to facilitate asset sales and disposition activities.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10070,"accession_number":"0001193125-26-278582","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Item 1.01 discloses entry into a material definitive agreement, specifically stalking horse asset purchase agreements. This indicates the company is engaged in a material acquisition or disposition process. The reference to Item 1.03 (bankruptcy-related asset sales) combined with stalking horse agreements—a mechanism used in bankruptcy proceedings to facilitate asset sales—suggests this is part of a broader M\u0026A or restructuring activity that would materially affect investors' assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13041,"run_id":11569,"accession_number":"0001193125-26-278582","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Sangamo disclosed the creation of a debtor-in-possession (DIP) financing facility of up to $30 million from Northridge ATM, LLC, which constitutes a new direct financial obligation subject to court approval.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10072,"accession_number":"0001193125-26-278582","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Sangamo has disclosed the creation of a debtor-in-possession (DIP) financing facility of up to $30 million from Northridge ATM, LLC, which constitutes a new direct financial obligation. While the DIP Facility is subject to court approval and the company is in Chapter 11 bankruptcy proceedings, the disclosure under Item 2.03 reflects the creation of a material debt obligation. This is classified as debt_issuance rather than bankruptcy_filing because the principal event disclosed is the financing arrangement itself, not the bankruptcy filing (which would have been disclosed separately as a bankruptcy_filing under Item 1.03).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13042,"run_id":11569,"accession_number":"0001193125-26-278582","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The Board approved a restructuring eliminating approximately 51 roles (40% of workforce) with expected incremental expenses of $3.0–$4.0 million in severance and employee health benefits.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10073,"accession_number":"0001193125-26-278582","item_number":"2.05","item_title":"Costs Associated With Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes a Board-approved restructuring eliminating approximately 51 roles (40% of workforce) with expected incremental expenses of $3.0–$4.0 million in severance and employee health benefits. This is a classic workforce reduction event under Item 2.05, with material financial and operational consequences disclosed under the proper Item heading.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10070,"accession_number":"0001193125-26-278582","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Item 1.01 discloses entry into a material definitive agreement, specifically stalking horse asset purchase agreements. This indicates the company is engaged in a material acquisition or disposition process. The reference to Item 1.03 (bankruptcy-related asset sales) combined with stalking horse agreements—a mechanism used in bankruptcy proceedings to facilitate asset sales—suggests this is part of a broader M\u0026A or restructuring activity that would materially affect investors' assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23"},{"id":10071,"accession_number":"0001193125-26-278582","item_number":"1.03","item_title":"Bankruptcy or Receivership.","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. The company will operate as a debtor-in-possession and has filed motions for first-day relief and debtor-in-possession financing. This is an unambiguous bankruptcy filing—a terminal event materially threatening the registrant's continued existence as an independent operating company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23"},{"id":10072,"accession_number":"0001193125-26-278582","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Sangamo has disclosed the creation of a debtor-in-possession (DIP) financing facility of up to $30 million from Northridge ATM, LLC, which constitutes a new direct financial obligation. While the DIP Facility is subject to court approval and the company is in Chapter 11 bankruptcy proceedings, the disclosure under Item 2.03 reflects the creation of a material debt obligation. This is classified as debt_issuance rather than bankruptcy_filing because the principal event disclosed is the financing arrangement itself, not the bankruptcy filing (which would have been disclosed separately as a bankruptcy_filing under Item 1.03).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23"},{"id":10073,"accession_number":"0001193125-26-278582","item_number":"2.05","item_title":"Costs Associated With Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes a Board-approved restructuring eliminating approximately 51 roles (40% of workforce) with expected incremental expenses of $3.0–$4.0 million in severance and employee health benefits. This is a classic workforce reduction event under Item 2.05, with material financial and operational consequences disclosed under the proper Item heading.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:46:58.850080+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-06-23"}]}